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Abstract
Background: In recent years, breast cancer (BC) mortality rates have declined, reflecting advances in early detection. Prevention and 
management of treatment sequelae that could impair function or quality of life have increased in relevance. Lymphoedema after BC 
treatment is one of these sequelae. It is caused by an acquired interruption or damage to the axillary lymphatic system and it is character-
ized by an abnormal accumulation of fluids and other substances in the tissue.
Purpose: We observed a group of patients with incidents of BC aiming to estimate the lymphoedema incidence, degree, time course, 
symptoms and treatment they received.
Methods and results: We evaluated 127 women. Median age was 58 years. 66% were postmenopausal. The median number of axillary 
nodes was 9. Over the first five years of follow-up we were informed about hand/arm swelling, thickness or tiredness by 37% of this 
group. The median of axillary nodes affected by metastatic cells in our patients with lymphoedema was 6. The symptoms they referred 
to us as the most relevant were heaviness (33%), tiredness (27%), jewelry or clothing too tight (25%), swelling and indentations (9%) 
and difficulty writing (6%). Several of them had psychological problems.
Conclusion: We know of the relevance of lymphoedema in BC patients but its natural history and most effective therapies are poorly 
understood. Self-reported symptoms are relevant to promptly start therapy.
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Introduction
In recent years, breast cancer (BC) mortality rates 
have declined,1 reflecting advances in early detection. 
Recently, the proportion of newly diagnosed women 
who have stage 0 or very favorable stage I BC have 
increased. Consequently many women diagnosed with 
BC can expect survival that is similar to age-matched 
women without BC as a result of improvements in 
diagnosis methods and effective adjuvant therapies.2 
The number of BC survivors has also substantially 
increased.3
As a result of these two points, prevention and man-
agement of treatment sequelae that could impair function 
or quality of life have acquired increased relevance.
Upper limb edema after BC surgery or radiation 
therapy is one of these sequelae,1,4,5 and is one of the 
most feared long-term complications. This is called 
lymphoedema and is due to an acquired   interruption 
or  damage  to  the  axillary  lymphatic  system  after 
locoregional treatment for BC6 and is characterized 
by an abnormal accumulation of fluids and other sub-
stances in the tissue.7
Lymphoedema can cause profound adverse effects 
on BC survivors’ quality of life.8
It causes physical discomfort, disfigurement, swell-
ing, pain, loss of sensation and functional impairment.6 
It can also cause anxiety, depression and emotional 
distress affecting social relationships and undermin-
ing body image.1
The reported incidence rates of this   complication 
range from 0% to 70% according to several series 
depending on how the condition was defined and mea-
sured and also how long the patients were   followed 
and observed.9,10
These  inconsistencies  in  measuring  and  defin-
ing the complication remain barriers to research and 
documentation.
After axillary lymph node dissection the incidence 
of lymphoedema is about 23%–38% if the criterion 
used to identify it is a greater than 2 cm increase in 
upper arm circumference measured at two adjacent 
points  compared  with  the  circumferences  of  the 
other arm.11–13 But professionals have highlighted the 
  relevance of patient self-reporting which is a param-
eter increasingly used alone or combined with arm 
measurement to study lymphoedema.11
Usually it there is a substantial delay between the 
initial  treatment  of  BC  and  clinical  appearance  of 
lymphoedema,12 although its   physiopathological onset 
is quick after treatment, but without clinical transla-
tion.  Thereafter  the  chronically  swollen  limb  may 
remain relatively stable for several years.12 In most 
cases it develops to be clinically visible within 3 years 
after treatment11 although most occur within the first 
2 years.
There are consistent risk factors for the   development 
of this complication such as obesity, lack of mobil-
ity, post-operative wound infection, radiotherapy to 
the axilla, full axillary nodes dissection, post-surgical 
drainage time and chemotherapy.13–20
One of the most important points to note is the 
lack of awareness of the condition by women at risk. 
A number of efforts have to be made to reduce the 
risk of secondary lymphoedema by pre-operative and 
post-operative counseling and education and by early 
detection.21,22
A randomised clinical trial on the prevention of 
secondary  lymphoedema  through  exercises  and  an 
educational strategy, however lacked sufficient evi-
dence to support use of this strategy.23
The  study  by  Lacomba  et  al  showed  that  early 
physiotherapy could be an effective intervention to 
prevent  secondary  lymphoedema  in  women  for  at 
least one year after surgery for BC and dissection of 
axillary lymph nodes.6
Lymphedema remains a problem even with mod-
ern  treatment  modalities.24,25  With  the  introduction 
of sentinel lymph node biopsy for axillary staging, it 
was assumed that this procedure would be associated 
with minimal morbidity as compared with full axil-
lary node dissection.26 But several studies have indi-
cated that sentinel lymph node dissection does indeed 
reduce but not eliminate the risk of lymphedema.27,28
With this controversial topic we decided to observe 
a group of patients with incident BC diagnosed in the 
second half of 2004 and in 2005 at our institution and 
followed over 5 years. We attempted to estimate the 
subjective  incidence  of  lymphoedema,  its  degree, 




After institutional review board approvals, we pro-
spectively recruited patients with first diagnosis of 
histologically confirmed invasive primary BC.Breast cancer and lymphoedema
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All eligible women were older than 18 years and 
physically and mentally capable of taking a clinical 
interview and reporting symptoms by themselves. All 
of them have undergone an axillary dissection as a 
part of their initial treatment.
We  excluded  patients  with  stage  IV  disease. 
All these women had been previously informed about 
the risk of lymphoedema and they were advised to 
consult in case of any symptoms on their upper limbs 
even if they were not related to swelling. All of them 
were informed before surgery by a surgeon and an 
oncologist. They received information about every 
symptom they could present and about the impact 
these symptoms could have in their lives. The   severity 
of this condition was identified by the patients in a 
subjective manner, according to the impact it had in 
their lives as mild, moderate or severe.
We aimed to record the first symptom they com-
plained about and the rest of parameters presented 
above.
With this objective we considered lymphoedema 
in  every  case  the  patient  reported  of  heaviness, 
sweelling or tiredness that appeared after surgery. 
The  inconsistencies  in  defining  this  complication 
remain  a  barrier  to  increasing  the  knowledge  we 
have about lymphoedema after BC, so we tried to 
identify and measure the incidence of the symptom-
atic condition as they were referred subjectively by 
our patients.
This cohort of patients were visited by a doctor 
every six months and if they referred symptoms they 
were visited whenever they needed.
Data analysis
Each woman’s follow-up period started on the date 
they underwent surgery with axillary dissection and 
we considered the date in which they complained as 
the moment of first event appearance.
We have presented the data in a descriptive way. 
The data were collected by a doctor.
Results
We  evaluated  127  women  diagnosed  with  BC  in 
our institution over the second half of 2004 and the 
whole year 2005. Median age was 58 years old (range 
between 28 to 79 years) being 66% postmenopausal.
The median number of axillary nodes analysed was 
9 (ranging between 4 and 17). 62% of them received 
adjuvant chemotherapy and 72% were treated with 
radiotherapy.
Over  the  first  five  years  of  follow-up  we  were 
informed about hand/arm swelling, thickness or tired-
ness by 37% of the group. 13% noticed it after the 
surgery was performed and the rest recognized it after 
the second or third year.
The majority of patients with lymphoedema accord-
ing our definition noticed changes in their symptoms 
and signs throughout the day reporting more intense 
swelling or disturbances at night. Exclusively in eight 
cases we were informed about this complication once 
they presented the whole arm with oedema without 
fluctuation throughout the day.
The median quantity of axillary nodes affected by 
metastatic cells in our patients with lymphoedema 
was 6 (ranging between 0–10).
The symptoms they referred to us as the most rele-
vant were heaviness (33%), tiredness (27%), jewelry 
or clothing too tight (25%), swelling and indentations 
(9%) and difficulty writing (6%).
For each symptom noticed, patients subjectively 
indicated the severity and level of associated distress 
and functional impairment.
67% of women reported symptoms as mild, 25% 
as  moderate  and  the  rest  as  very  severe.  On  the 
other hand, most of these patients had some kind of 
  depression or discouragement, mainly patients with 
severe lymphoedema and arm function impairment 
with difficulties to perform daily activities or in case 
of cosmetic deterioration.
After being informed about the appearance of this 
complication we sent the patients for evaluation by 
an occupational therapist. Women experiencing mod-
erate  or  severe  lymphoedema  were  more  likely  to 
be treated than those with only mild lymphoedema. 
Among treated patients the majority received graded 
compression  garments  to  deliver  pressures  to  the 
affected arm. Others were advised to perform some 
form of exercise, to receive massages or to elevate 
the arm.
All of them were taught to protect their arms to 
avoid cuts, burns, bites and cannulae, to treat minor 
wounds promptly to avoid infection and to avoid pres-
sure around the arm from blood pressure tourniquets 
and tight clothing and to avoid carrying heavy loads.
Patients who reported some degree of discourage-
ment were advised to visit a psychologist. In three Cidón et al
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cases the patients needed to visit a psychiatric clinic 
foranti-depressive treatment.
After  the  treatment  commenced  all  of  them 
reported clinical improvement in their physical chan-
ges, locore  gional symptoms and emotional or distress 
problems.
Discussion
Lymphoedema represents potentially the most debili-
tating complication after nodal axillary surgical dis-
section in patients diagnosed with BC.29
Due to the lack of a standardized definition of lym-
phoedema, we do not know its true incidence and it 
can be difficult to determine.30 Previous studies have 
found rates of lymphoedema of 0% to 70% depend-
ing on how the condition was defined or how long the 
sample was followed.9,10,31 Although volume displace-
ment techniques are recognized as the gold standard 
in assessing this complication, this technique can be 
cumbersome in a busy clinical setting. This is the 
reason why the majority of clinical series have used 
circumferential measurements of the upper arm and 
forearm as surrogate markers for volume change.32–34 
However those measurements may be unrealistic for 
all studies evaluating lymphoedema rates after BC 
treatment, and therefore a common agreement on ter-
minology is relevant. Many authors have developed 
a validated self-administered questionnaire that cor-
relates well with these measurements.35 But others 
have found different definitions and measurements 
of lymphoedema which were not equivalent.36 On the 
other  hand  they  have  suggested  that  self-reporting 
of  signs  and  symptoms  might  not  be  as  good  as 
using an objective definition of a 2 cm increase in 
arm   circumference37 as the contrary has been dem-
onstrated  by  another  study.38  A  recent  study  also 
demonstrated  that  differences  in    self-reported  arm 
size and symptoms can be early signs of progress-
ing   lymphoedema.39 This is the reason for our use of 
self-reported  symptoms  to  evaluate  the  symptoms 
reported by patients who underwent BC surgery.
As  a  conclusion,  the  problem  associated  with 
the objective measurements has been the necessity 
of baseline data to precisely determine changes in 
arm size which is not always possible in a clini-
cal   setting. In such cases the patients who referred 
  subjective  limb  symptoms  must  be  referred  to  a 
physical therapist.40
As we have shown above, in our study the   majority 
of symptomatic patients after BC therapy reported a 
feeling of arm heaviness followed by arm tiredness 
and jewelry or clothing being too tight. These symp-
toms have to be considered as the early manifestation 
of subtle lymphoedema and they lead us to send these 
patients to a physical therapist to begin a fluid man-
agement treatment quickly.
The importance of mild lymphoedema is   becoming 
clearer.41,42  Although  lymphoedema  is  a  common 
sequalae  of  BC,  most  lymphoedemas  are  mild. 
The wide range of reported incidences reflects the dif-
ference among studies’ end-points measured.
Recent prospective studies have shown 3-year rates 
of lymphoedema varying from 15% to 54%.41,43 The 
first  two  studies43,44  used  circumferential  measure-
ments and the third and fourth studies assessed arm 
swelling by self-report.41,45 Our finding of a 37% inci-
dence of this complication after 3 years falls within 
this range of estimates.
Our results confirm the finding that most of the cases 
with lymphoedema are mild, and also   demonstrate 
that  multiple  symptoms  are  associated  with  subtle 
lymphoedema, such as jewelry being too tight.
Only by observing a well-described and enumer-
ated group of women over time we can obtain accu-
rate estimates of cumulative incidence or risk as well 
as progression and regression of this condition.
This  prospective  population-based  study  has 
addressed incidence, degree, and time course of lym-
phoedema in BC survivors who report symptoms by 
themselves.
Subtle differences in self-reported arm/hand size 
can  be  early  signs  of  progressing  lymphoedema. 
Whether prompt treatment when symptoms appear 
might help to avoid any kind of objective lymphoe-
dema and whether progression from mild to   moderate/
severe lymphoedema could be slowed with earlier 
detection and treatment merit further investigation.
Although  we  know  several  risk  factors  which 
influence the development of lymphoedema we have 
not evaluated these in our study.
In the study by Yen et al they have found that 
removal of more than five lymph nodes and presence 
of lymph node metastases were independent predic-
tors of developing lymphoedema. Our study showed 
that the median number of lymph nodes examined 
was  9,  meanwhile  the  median  number  of  nodes Breast cancer and lymphoedema
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affected  among  patients  with  lymphoedema  was  6 
being similar to the ones indicated above.
Recently,  the  sentinel  lymph  node  biopsy  have 
resulted in significantly less frequent lymphoedema 
than axillary lymph node dissection.46 At a median 
of 5 years after this procedure, 5% of women will 
develop lymphoedema although this proportion will 
continue to increase with time because data related to 
lymphoedema after axillary dissection suggest that the 
large majority of those who will ultimately develop it 
have done so by 5 years.21 As a conclusion, although 
this  technique  has  certainly  reduced  the  morbidity 
associated with axillary staging for BC, there remains 
a small but significant risk of lymphoedema.
Finally, and due to psychological morbidity asso-
ciated with lymphoedema, psychosocial issues should 
be promptly recognized and addressed. Women with 
lymphoedema have shown to have greater psychiatric 
morbidity and functional disability and so they will 
experience a deterioration in their quality of life.46 
Our study has shown that patients who reported some 
kind of discouragment were encouraged to promptly 
visit a psychologist and in three cases the patients 
visited a phychiatric clinic to start an anti-depressive 
treatment. All these case showed an improvement in 
their anxiety problems.
Although we know the relevance of lymphoedema 
in BC patients, its natural history and most effective 
therapies have been poorly understood and need fur-
ther study. Accurate assessment requires agreement 
on a standardized and reliable system of measure-
ment. Randomized controlled trials to answer these 
questions should be encouraged.
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